148 related articles for article (PubMed ID: 16804830)
1. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.
Lee CA; Lillicrap D; Astermark J
Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():10-4. PubMed ID: 16804830
[TBL] [Abstract][Full Text] [Related]
2. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
Gouw SC; van den Berg HM
Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
[TBL] [Abstract][Full Text] [Related]
3. Genetic risk factors for inhibitors to factors VIII and IX.
Oldenburg J; Pavlova A
Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
[TBL] [Abstract][Full Text] [Related]
4. The epidemiology of factor VIII inhibitors.
Hay CR
Haemophilia; 2006 Dec; 12 Suppl 6():23-8; discussion 28-9. PubMed ID: 17123390
[TBL] [Abstract][Full Text] [Related]
5. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
6. Treatment related factors and inhibitor development in children with severe haemophilia A.
Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
[TBL] [Abstract][Full Text] [Related]
7. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of inhibitors in mild/moderate haemophilia A.
Peerlinck K; Jacquemin M
Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
[TBL] [Abstract][Full Text] [Related]
9. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
[TBL] [Abstract][Full Text] [Related]
10. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
11. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
Gomperts ED
Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
[TBL] [Abstract][Full Text] [Related]
12. Risk of inhibitor development in mild haemophilia A increases with age.
Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
[TBL] [Abstract][Full Text] [Related]
13. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.
Coppola A; Santoro C; Tagliaferri A; Franchini M; DI Minno G
Haemophilia; 2010 Jan; 16 Suppl 1():13-9. PubMed ID: 20059564
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.
Bafunno V; Santacroce R; Chetta M; D'Andrea G; Pisanelli D; Sessa F; Trotta T; Tagariello G; Peyvandi F; Margaglione M
Haemophilia; 2010 May; 16(3):469-73. PubMed ID: 20015215
[TBL] [Abstract][Full Text] [Related]
15. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
d'Oiron R; Volot F; Reynaud J; Peerlinck K; Goudemand J; Guérois C; Rothschild C; Chambost H; Borel-Derlon A; Roussel-Robert V; Marquès-Verdier A; Lienhart A; Berthier AM; Moreau P; Lambert T;
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S3-9. PubMed ID: 16427382
[TBL] [Abstract][Full Text] [Related]
16. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
Astermark J
Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
[TBL] [Abstract][Full Text] [Related]
18. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
Astermark J
Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
[TBL] [Abstract][Full Text] [Related]
19. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
Astermark J; Oldenburg J; Escobar M; White GC; Berntorp E;
Haematologica; 2005 Jul; 90(7):924-31. PubMed ID: 15996930
[TBL] [Abstract][Full Text] [Related]
20. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
